Genetic variation in a metabolic signaling pathway and colon and rectal cancer risk: mTOR, PTEN, STK11, RPKAA1, PRKAG2, TSC1, TSC2, PI3K and Akt1.

Serine/threonine protein kinase 11 (STK11) and phosphatase tensin homolog deleted on chromosome 10 (PTEN) link insulin sensitivity and metabolic signaling to inflammation and other hormonal factors and colorectal cancer. We evaluate genetic variation in nine genes in a candidate pathway as follows: STK11 (3 tagSNPs), PTEN (9 tagSNPs), FRAP1 (mTOR) (4 tagSNPs), TSC1 (14 tagSNPs), TSC2 (8 tagSNPs), Akt1 (2 tagSNPs), PIK3CA (7 tagSNPs), PRKAA1 (13 tagSNPs) and PRKAG2 (68 tagSNPs) in two population-based case-control studies of colon (n = 1574 cases, 1940 controls) and rectal (n = 91 cases, 999 controls) cancer. FRAP1, PRKAA1, PRKAG2 and TSC2 genes were significantly associated with colon cancer; risk estimates ranged from 1.21 [95% confidence interval (CI) 1.05-1.38] for FRAP1rs1057079 for the AG/GG genotype to 1.51 (95% CI 1.09-2.09) for PRKAG2rs9648723 CC genotype. PIK3CA, PRKAG2, PTEN, STK11 and TSC1 were significantly associated with rectal cancer overall. The strongest association was observed for PIK3CA rs7651265 GG genotype (odds ratio 2.32 95% CI 1.02-5.30). FRAP1 was associated with microsatellite instability (MSI)+ colon tumors; PRKAA1, CpG island methylator phenotype (CIMP)+ and MSI+ colon tumors; PRKAG2 and KRAS2 colon tumors; TSC1 and CIMP+ and MSI+ colon tumors; TSC2 with MSI+ colon tumors; PIK3CA with KRAS2-mutated rectal tumors; PRKAG2 (rs6964824) with KRAS2- and TP53-mutated rectal tumors and with PRKAG2 (rs412396 and rs4725431) with CIMP+ rectal tumors. These data suggest that genetic variation in a predefined candidate pathway for colorectal cancer contributes to both colon and rectal cancer risk. Associations appear to be strongest for CIMP+ and MSI+ tumors.

[1]  C. Sawyers,et al.  The phosphatidylinositol 3-Kinase–AKT pathway in human cancer , 2002, Nature Reviews Cancer.

[2]  Jérôme Boudeau,et al.  Complexes between the LKB1 tumor suppressor, STRADα/β and MO25α/β are upstream kinases in the AMP-activated protein kinase cascade , 2003, Journal of biology.

[3]  Y. Benjamini,et al.  More powerful procedures for multiple significance testing. , 1990, Statistics in medicine.

[4]  G. Casey,et al.  The AKT/IκB kinase pathway promotes angiogenic/metastatic gene expression in colorectal cancer by activating nuclear factor-κB and β-catenin , 2005, Oncogene.

[5]  G. Casey,et al.  The AKT/I kappa B kinase pathway promotes angiogenic/metastatic gene expression in colorectal cancer by activating nuclear factor-kappa B and beta-catenin. , 2005, Oncogene.

[6]  J. Potter,et al.  Body mass index and colon cancer: an evaluation of the modifying effects of estrogen (United States) , 2003, Cancer Causes & Control.

[7]  R. Wolff,et al.  A Comparison of Colon and Rectal Somatic DNA Alterations , 2009, Diseases of the colon and rectum.

[8]  F. Fitzpatrick,et al.  Akt activation by arachidonic acid metabolism occurs via oxidation and inactivation of PTEN tumor suppressor , 2007, Oncogene.

[9]  Gang Zheng,et al.  On estimation of the variance in Cochran–Armitage trend tests for genetic association using case–control studies , 2006, Statistics in medicine.

[10]  David Carling,et al.  The AMP-activated protein kinase cascade--a unifying system for energy control. , 2004, Trends in biochemical sciences.

[11]  J. Potter,et al.  Hormone replacement therapy, reproductive history, and colon cancer: a multicenter, case-control study in the United States , 1997, Cancer Causes & Control.

[12]  G. Hortobagyi,et al.  IKKβ Suppression of TSC1 Links Inflammation and Tumor Angiogenesis via the mTOR Pathway , 2007, Cell.

[13]  C. Carlson,et al.  Selecting a maximally informative set of single-nucleotide polymorphisms for association analyses using linkage disequilibrium. , 2004, American journal of human genetics.

[14]  N. Camp,et al.  Classification tree analysis: a statistical tool to investigate risk factor interactions with an example for colon cancer (United States) , 2002, Cancer Causes & Control.

[15]  T D Berry,et al.  A computerized diet history questionnaire for epidemiologic studies. , 1994, Journal of the American Dietetic Association.

[16]  R. Moon,et al.  The Tuberin-Hamartin Complex Negatively Regulates β-Catenin Signaling Activity* , 2003, The Journal of Biological Chemistry.

[17]  R. Wolff,et al.  Diet and lifestyle factor associations with CpG island methylator phenotype and BRAF mutations in colon cancer , 2007, International journal of cancer.

[18]  David Carling,et al.  Supplemental Data LKB 1 Is the Upstream Kinase in the AMP-Activated Protein Kinase Cascade , 2003 .

[19]  C. Ulrich,et al.  Assessing Tumor Mutations to Gain Insight into Base Excision Repair Sequence Polymorphisms and Smoking in Colon Cancer , 2009, Cancer Epidemiology, Biomarkers & Prevention.

[20]  R. Moon,et al.  The tuberin-hamartin complex negatively regulates beta-catenin signaling activity. , 2003, The Journal of biological chemistry.

[21]  J. Potter,et al.  Energy balance and colon cancer--beyond physical activity. , 1997, Cancer research.

[22]  M. Leppert,et al.  Associations between cigarette smoking, lifestyle factors, and microsatellite instability in colon tumors. , 2000, Journal of the National Cancer Institute.

[23]  R. DePinho,et al.  The LKB1 tumor suppressor negatively regulates mTOR signaling. , 2004, Cancer cell.

[24]  M. White,et al.  Signaling Pathways: The Benefits of Good Communication , 2004, Current Biology.

[25]  W. Cook,et al.  Accommodating haploinsufficient tumour suppressor genes in Knudson's model , 2000, Oncogene.

[26]  T D Berry,et al.  Objective system for interviewer performance evaluation for use in epidemiologic studies. , 1994, American journal of epidemiology.

[27]  R. Wolff,et al.  Tumor markers and rectal cancer: Support for an inflammation‐related pathway , 2009, International journal of cancer.

[28]  M. Slattery,et al.  Convergence of Hormones, Inflammation, and Energy-Related Factors: A Novel Pathway of Cancer Etiology , 2009, Cancer Prevention Research.

[29]  M. Leppert,et al.  Relationship of Ki-ras mutations in colon cancers to tumor location, stage, and survival: a population-based study. , 2000, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

[30]  B. Manning,et al.  Common corruption of the mTOR signaling network in human tumors , 2008, Oncogene.

[31]  F. Fitzpatrick,et al.  Reactive Lipid Species from Cyclooxygenase-2 Inactivate Tumor Suppressor LKB1/STK11 , 2006, Journal of Biological Chemistry.

[32]  D. Hardie.  Printed in U.S.A. Copyright © 2003 by The Endocrine Society doi: 10.1210/en.2003-0982 Minireview: The AMP-Activated Protein Kinase Cascade: The Key Sensor of Cellular Energy Status , 2022 .

[33]  M. Boehnke,et al.  So many correlated tests, so little time! Rapid adjustment of P values for multiple correlated tests. , 2007, American journal of human genetics.

[34]  Lewis C Cantley,et al.  The tumor suppressor LKB1 kinase directly activates AMP-activated kinase and regulates apoptosis in response to energy stress. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[35]  B. Viollet,et al.  Physiological role of AMP-activated protein kinase (AMPK): insights from knockout mouse models. , 2001, Biochemical Society transactions.

[36]  M. Slattery,et al.  Body size and the risk of colon cancer in a large case-control study , 1998, International Journal of Obesity.

[37]  M. Hung,et al.  All Roads Lead to mTOR: Integrating Inflammation and Tumor Angiogenesis , 2007, Cell cycle.

[38]  D. Alessi,et al.  The role of PI 3-kinase in insulin action. , 1998, Biochimica et biophysica acta.

[39]  G. Ning,et al.  Glucose and lipid metabolism in relation to novel polymorphisms in the 5'-AMP-activated protein kinase gamma2 gene in Chinese. , 2005, Molecular genetics and metabolism.

[40]  Z. Shao,et al.  The tumor suppressor gene LKB1 is associated with prognosis in human breast carcinoma. , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.

[41]  M. Slattery,et al.  Energy Balance and Rectal Cancer: An Evaluation of Energy Intake, Energy Expenditure, and Body Mass Index , 2003, Nutrition and cancer.

[42]  N. Camp,et al.  A breast cancer risk haplotype in the caspase-8 gene. , 2009, Cancer research.

[43]  C Eng,et al.  Will the real Cowden syndrome please stand up (again)? Expanding mutational and clinical spectra of the PTEN hamartoma tumour syndrome , 2004, Journal of Medical Genetics.

[44]  D. Hardie.  The AMP-activated protein kinase pathway – new players upstream and downstream , 2004, Journal of Cell Science.

[45]  J. Herman,et al.  Epigenetic inactivation of LKB1 in primary tumors associated with the Peutz-Jeghers syndrome , 2000, Oncogene.

[46]  S. Neuhausen,et al.  Aspirin, NSAIDs, and colorectal cancer: possible involvement in an insulin-related pathway. , 2004, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

[47]  M. Leppert,et al.  Prognostic significance of p53 mutations in colon cancer at the population level , 2002, International journal of cancer.

[48]  W. Friedrichs,et al.  Reduced PTEN expression in breast cancer cells confers susceptibility to inhibitors of the PI3 kinase/Akt pathway. , 2004, Annals of oncology : official journal of the European Society for Medical Oncology.